Int Immunopharmacol 2023, 119: 110201
Data Validation and Update Cycle: Findings were validated through expert review and aligned with recent treatment, approval, and usage data
While semaglutide has 94% structural homology to native human GLP-1, modifications have been made to extend its t to approximately 1 week in humans, allowing once-weekly administration [18, 21]
Retatrutide simultaneously targets GLP-1, GIP, and glucagon receptors a mechanism that sets it apart from approved agents such as semaglutide and tirzepatide
As the body's primary endogenous antioxidant, it plays a critical role in neutralizing free radicals, regenerating other antioxidants like vitamins C and E, and maintaining cellular health and longevity 1-4
PubMed Central PMCID: PMC4863553